Ulla Wilking

831 total citations
20 papers, 608 citations indexed

About

Ulla Wilking is a scholar working on Oncology, Cancer Research and Economics and Econometrics. According to data from OpenAlex, Ulla Wilking has authored 20 papers receiving a total of 608 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Cancer Research and 6 papers in Economics and Econometrics. Recurrent topics in Ulla Wilking's work include Breast Cancer Treatment Studies (8 papers), HER2/EGFR in Cancer Research (8 papers) and Economic and Financial Impacts of Cancer (6 papers). Ulla Wilking is often cited by papers focused on Breast Cancer Treatment Studies (8 papers), HER2/EGFR in Cancer Research (8 papers) and Economic and Financial Impacts of Cancer (6 papers). Ulla Wilking collaborates with scholars based in Sweden, Netherlands and United Kingdom. Ulla Wilking's co-authors include Jonas Bergh, Eva Karlsson, Lambert Skoog, Linda S. Lindström, Thomas Hatschek, Elisabet Lidbrink, Johan Hartman, Ulla Johansson, Göran Elmberger and Nils Wilking and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Nature Reviews Clinical Oncology.

In The Last Decade

Ulla Wilking

19 papers receiving 597 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ulla Wilking Sweden 7 460 330 171 134 95 20 608
Reshma Mahtani United States 14 438 1.0× 194 0.6× 229 1.3× 110 0.8× 142 1.5× 80 630
Isabelle Desmoulins France 15 361 0.8× 271 0.8× 205 1.2× 191 1.4× 84 0.9× 75 624
Angela Sciandivasci Italy 11 425 0.9× 286 0.9× 191 1.1× 85 0.6× 100 1.1× 23 593
Maggie Wilcox United Kingdom 6 340 0.7× 304 0.9× 168 1.0× 42 0.3× 65 0.7× 9 512
Winfried Schoenegg Germany 13 354 0.8× 242 0.7× 194 1.1× 70 0.5× 206 2.2× 24 636
Ivana Božović‐Spasojević Belgium 8 299 0.7× 259 0.8× 111 0.6× 58 0.4× 159 1.7× 17 501
Erik J. Blok Netherlands 13 342 0.7× 269 0.8× 180 1.1× 47 0.4× 97 1.0× 19 548
Lisette Stork‐Sloots United States 13 399 0.9× 451 1.4× 94 0.5× 64 0.5× 148 1.6× 49 633
A. Goldhirsch Italy 15 537 1.2× 382 1.2× 143 0.8× 88 0.7× 135 1.4× 39 825
D.J.A. Lobbezoo Netherlands 8 378 0.8× 256 0.8× 261 1.5× 57 0.4× 40 0.4× 14 490

Countries citing papers authored by Ulla Wilking

Since Specialization
Citations

This map shows the geographic impact of Ulla Wilking's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulla Wilking with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulla Wilking more than expected).

Fields of papers citing papers by Ulla Wilking

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulla Wilking. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulla Wilking. The network helps show where Ulla Wilking may publish in the future.

Co-authorship network of co-authors of Ulla Wilking

This figure shows the co-authorship network connecting the top 25 collaborators of Ulla Wilking. A scholar is included among the top collaborators of Ulla Wilking based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulla Wilking. Ulla Wilking is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fredriksson, Irma, Ulla Wilking, Jonas Bergh, et al.. (2023). Risk-adjusted benchmarking of long-term overall survival in patients with HER2-positive early-stage Breast cancer: A Swedish retrospective cohort study. The Breast. 70. 18–24. 1 indexed citations
2.
Johnsson, Aina, Narsis A. Kiani, Sofie A. M. Gernaat, et al.. (2023). Planning for return to work during the first year after breast cancer metastasis: A Swedish cohort study. Cancer Medicine. 12(9). 10840–10850. 2 indexed citations
3.
Altena, Renske, Sofie A. M. Gernaat, Ulla Wilking, et al.. (2022). Use of sickness benefits by patients with metastatic breast cancer—A Swedish cohort study. European Journal of Cancer Care. 31(5). e13626–e13626. 2 indexed citations
4.
Pignatti, Francesco, Ulla Wilking, Douwe Postmus, et al.. (2021). The value of anticancer drugs — a regulatory view. Nature Reviews Clinical Oncology. 19(3). 207–215. 23 indexed citations
5.
Gernaat, Sofie A. M., Aina Johnsson, Renske Altena, Ulla Wilking, & Elham Hedayati. (2020). Sickness absence and disability pension among swedish women prior to breast cancer relapse with a special focus on the roles of treatment and comorbidity. European Journal of Cancer Care. 30(1). e13353–e13353. 5 indexed citations
6.
Hedayati, Elham, Sofie A. M. Gernaat, Aina Johnsson, Ulla Wilking, & Renske Altena. (2020). Sickness absence and disability pension among Swedish women before breast cancer relapse.. Journal of Clinical Oncology. 38(15_suppl). e14121–e14121. 1 indexed citations
7.
Wilking, Nils, Bengt Jönsson, Peter Lindgren, & Ulla Wilking. (2017). Does access to cancer drugs relate to survival benefit? A European study in countries with different economic status.. Journal of Clinical Oncology. 35(15_suppl). 6535–6535. 1 indexed citations
8.
9.
Wilking, Nils, Peter Lindgren, Ulla Wilking, & Bengt Jönsson. (2016). Access to cancer drugs in Europe years 2005-2014.. Journal of Clinical Oncology. 34(15_suppl). e18015–e18015. 1 indexed citations
10.
Wilking, Nils, Ulla Wilking, & Bengt Jönsson. (2014). The positioning of economic principles under the changing conditions of the novel drug developmental process in cancer.. PubMed. 3(2). 23–23. 2 indexed citations
11.
Lindström, Linda S., Alexandra Jauhiainen, Ulla Wilking, et al.. (2013). Abstract P6-06-17: Gene signature model predicts metastatic onset better than standard clinical markers - Nested case-control design uniquely enables enrichment for biologically relevant features. Cancer Research. 73(24_Supplement). P6–6. 5 indexed citations
12.
Lindström, Linda S., Eva Karlsson, Ulla Wilking, et al.. (2012). Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression. Journal of Clinical Oncology. 30(21). 2601–2608. 370 indexed citations
13.
Wilking, Ulla, Bengt Jönsson, Nils Wilking, & Jonas Bergh. (2010). Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden. Acta Oncologica. 49(6). 844–850. 11 indexed citations
14.
Wilking, Ulla, Eva Karlsson, Lambert Skoog, et al.. (2010). HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Research and Treatment. 125(2). 553–561. 94 indexed citations
15.
Wilking, Ulla, et al.. (2010). Abstract P1-09-05: Re-Testing of HER2 Status in Recurring Metastatic Breast Cancer Is a Clinically Relevant and Cost-Effective Strategy. Cancer Research. 70(24_Supplement). P1–9. 1 indexed citations
16.
Karlsson, Emelié, Leena Lindström, Ulla Wilking, et al.. (2010). Discordance in hormone receptor status in breast cancer during tumor progression.. Journal of Clinical Oncology. 28(15_suppl). 1009–1009. 33 indexed citations
17.
Lindström, Linda S., Elin Karlsson, Ulla Wilking, & Jonas Bergh. (2010). Abstract S3-5: Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression. Cancer Research. 70(24_Supplement). S3–5. 4 indexed citations
18.
Wilking, Ulla, Lambert Skoog, Göran Elmberger, et al.. (2009). HER-2/neu expression/amplification is not stable during tumor progression. A single institution study with intrapatient comparisons years 1999 through to 2007.. Cancer Research. 69(2_Supplement). 6033–6033. 3 indexed citations
19.
Wilking, Nils, et al.. (2009). Health Related Quality of Life (HRQoL) in Swedish Relapse Free Breast Cancer Patients. A Study of EQ5D and TTO in a Patient Advocacy Population.. Cancer Research. 69(24_Supplement). 5047–5047. 1 indexed citations
20.
Wilking, Ulla, Lambert Skoog, Göran Elmberger, Nils Wilking, & Jonas Bergh. (2007). HER2 gene amplification (HER2) and hormone receptor expression (ER/PR) in early (EBC) and metastatic breast cancer (MBC) in the same patients. Journal of Clinical Oncology. 25(18_suppl). 1023–1023. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Reshma Mahtani Breakdown of academic impact, for papers by Isabelle Desmoulins Breakdown of academic impact, for papers by Angela Sciandivasci Breakdown of academic impact, for papers by Maggie Wilcox Breakdown of academic impact, for papers by Winfried Schoenegg Breakdown of academic impact, for papers by Ivana Božović‐Spasojević Breakdown of academic impact, for papers by Erik J. Blok Breakdown of academic impact, for papers by Lisette Stork‐Sloots Breakdown of academic impact, for papers by A. Goldhirsch Breakdown of academic impact, for papers by D.J.A. Lobbezoo
Rankless by CCL
2026